Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and
accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal …

PURPOSE: To conduct a dose-escalation trial of rituximab in patients with chronic
lymphocytic leukemia (CLL) to define the maximum-tolerated dose (MTD), to evaluate first …

Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

The use of the anti-CD20 antibody rituximab has improved the outcome of patients with
chronic lymphocytic leukemia (CLL). Rituximab was shown to act via various mechanisms …

Rituximab is a class I chimeric anti-CD20 antibody that has shown efficacy in chronic
lymphocytic leukemia (CLL), both as a single agent and in combination with traditional …

Abstract Rituximab (Rituxan®; iogen Idec, San Diego, CA, USA) is a human-mouse chimeric
monoclonal antibody specific for CD20, a surface glycoprotein expressed on B lymphocytes …

We have reported that treatment of CLL patients with weekly RTX doses of 375 mg/m 2
depletes complement (C) and induces substantial loss (~ 90%) of CD20 on circulating cells …

OBJECTIVE: Anti-CD20 chimeric monoclonal antibody rituximab (Mabthera; IDEC-C2B8) is
currently tested in several clinical trials for the treatment of B-cell chronic lymphocytic …

Monoclonal antibodies in combination with chemotherapy allowed us to obtain more
responses and longer response duration in B-cell chronic lymphocytic leukemia (B-CLL) …

Chronic lymphocytic leukemia (CLL) remains incurable despite decades of clinical trials.
Some patients survive for long periods without requiring definitive therapy, while others die …